Aulos Bioscience
Cambridge
About Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics. Their initial clinical candidate, AU-007, stands apart from existing IL-2 therapeutics by introducing a novel approach that addresses a significant medical challenge of the present era: the eradication of cancer. Through harnessing the anti-cancer potential of interleukin-2, they are breaking down barriers in the field of immuno-oncology. Their distinctive immunotherapy, computationally designed to precisely guide the immune system in attacking tumor cells, is poised to make a substantial impact.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $60.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Aug 2023)
- Website: aulosbio.com
- Phone: (617) 294-6790
Industries & Categories
Biotechnology, Health Care, Life Science, Medical, Oncology
Social Profiles
Canonical: https://fsome.com/organization/aulos-bioscience-32967 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.